NCT02226666View on ClinicalTrials.gov

Physiologic Assessment Following Gadoxetic Acid and Gadobenate Dimeglumine Administration

CompletedOBSERVATIONAL
Enrollment

107

Participants

Timeline

Start Date

August 31, 2013

Primary Completion Date

December 31, 2015

Study Completion Date

December 31, 2015

Conditions
Liver Tumor
Interventions
DRUG

MRI with Multihance

Patients will have Multihance used as an IV contrast agent for their scan.

DRUG

MRI with Eovist

Patients will have Eovist used as an IV contrast agent for their scan.

Trial Locations (1)

48109

University of Michigan Hospital, Ann Arbor

All Listed Sponsors
lead

University of Michigan

OTHER

NCT02226666 - Physiologic Assessment Following Gadoxetic Acid and Gadobenate Dimeglumine Administration | Biotech Hunter | Biotech Hunter